Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-Amino‑3‑methyl‑1‑pyrrolidin‑1‑yl‑butan‑1‑one is a synthetic small molecule and a derivative of valine, featuring a pyrrolidine ring attached to the butanone backbone. It has been studied as an experimental compound and is not approved for medical use. Its primary mechanism of action is as an inhibitor of dipeptidyl peptidase 4 (DPP4), an enzyme involved in glucose metabolism and immune regulation. The compound has no known clinical indications or approved therapeutic uses, and it appears primarily in research contexts[2][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one.